Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas r&d expenses
Research and development expenses are spending on new products and technology.
Arvinas's R&D Expenses for the twelve months ending Jun 30, 2026 was $238.70M, down 27.6% year over year. For fiscal 2025 it was $285.20M, down 18.1% from the year before. The highest annual figure on record is $379.70M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.20M | -18.1% |
| FY2024 | Dec 31, 2024 | $348.20M | -8.3% |
| FY2023 | Dec 31, 2023 | $379.70M | +20.5% |
| FY2022 | Dec 31, 2022 | $315.00M | +74.6% |
| FY2021 | Dec 31, 2021 | $180.40M | +66.4% |
| FY2020 | Dec 31, 2020 | $108.40M | +61.3% |
| FY2019 | Dec 31, 2019 | $67.20M | +48.7% |
| FY2018 | Dec 31, 2018 | $45.19M | +57.0% |
| FY2017 | Dec 31, 2017 | $28.79M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $52.60M | -23.3% |
| Q1 FY2026 | Mar 31, 2026 | $60.30M | -33.6% |
| Q4 FY2025 | Dec 31, 2025 | $61.10M | -26.7% |
| Q3 FY2025 | Sep 30, 2025 | $64.70M | -25.5% |
| Q2 FY2025 | Jun 30, 2025 | $68.60M | -26.8% |
| Q1 FY2025 | Mar 31, 2025 | $90.80M | +7.7% |
| Q4 FY2024 | Dec 31, 2024 | $83.30M | -12.5% |
| Q3 FY2024 | Sep 30, 2024 | $86.90M | +1.2% |
| Q2 FY2024 | Jun 30, 2024 | $93.70M | -9.4% |
| Q1 FY2024 | Mar 31, 2024 | $84.30M | -11.5% |
| Q4 FY2023 | Dec 31, 2023 | $95.20M | -3.2% |
| Q3 FY2023 | Sep 30, 2023 | $85.90M | +10.8% |
| Q2 FY2023 | Jun 30, 2023 | $103.40M | +37.3% |
| Q1 FY2023 | Mar 31, 2023 | $95.30M | +48.9% |
| Q4 FY2022 | Dec 31, 2022 | $98.30M | +58.8% |
| Q3 FY2022 | Sep 30, 2022 | $77.50M | +90.9% |
| Q2 FY2022 | Jun 30, 2022 | $75.30M | +75.1% |
| Q1 FY2022 | Mar 31, 2022 | $64.00M | +83.4% |
| Q4 FY2021 | Dec 31, 2021 | $61.90M | +86.2% |
| Q3 FY2021 | Sep 30, 2021 | $40.60M | +35.3% |
| Q2 FY2021 | Jun 30, 2021 | $43.00M | +83.6% |
| Q1 FY2021 | Mar 31, 2021 | $34.90M | +60.6% |
| Q4 FY2020 | Dec 31, 2020 | $33.24M | +62.8% |
| Q3 FY2020 | Sep 30, 2020 | $30.01M | +80.9% |
| Q2 FY2020 | Jun 30, 2020 | $23.42M | +46.3% |
| Q1 FY2020 | Mar 31, 2020 | $21.73M | +53.1% |
| Q4 FY2019 | Dec 31, 2019 | $20.41M | +40.2% |
| Q3 FY2019 | Sep 30, 2019 | $16.59M | +26.1% |
| Q2 FY2019 | Jun 30, 2019 | $16.00M | +54.8% |
| Q1 FY2019 | Mar 31, 2019 | $14.19M | +98.6% |
| Q4 FY2018 | Dec 31, 2018 | $14.56M | +117.7% |
| Q3 FY2018 | Sep 30, 2018 | $13.15M | +82.1% |
| Q2 FY2018 | Jun 30, 2018 | $10.34M | +32.1% |
| Q1 FY2018 | Mar 31, 2018 | $7.14M | +1.2% |
| Q4 FY2017 | Dec 31, 2017 | $6.69M | – |
| Q3 FY2017 | Sep 30, 2017 | $7.22M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.06M | – |
See a number that looks wrong?